Outcomes and prognostic factors of differentiated thyroid cancer with bone metastasis
WANG Yan, ZHENG Rong, FAN Rong, LIN Lin, GENG Jianhua
Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021 China
王燕, 郑容, 樊蓉, 林琳, 耿建华. 分化型甲状腺癌骨转移的预后及影响因素[J]. 中国辐射卫生, 2023, 32(1): 46-51,61.
WANG Yan, ZHENG Rong, FAN Rong, LIN Lin, GENG Jianhua. Outcomes and prognostic factors of differentiated thyroid cancer with bone metastasis. Chinese Journal of Radiological Health, 2023, 32(1): 46-51,61.
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590 [2] Muresan MM, Olivier P, Leclère J, et al. Bone metastases from differentiated thyroid carcinoma[J]. Endocr Relat Cancer, 2008, 15(1): 37-49. DOI: 10.1677/ERC-07-0229 [3] Do MY, Rhee Y, Kim DJ, et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period[J]. Endocr J, 2005, 52(6): 701-707. DOI: 10.1507/endocrj.52.701 [4] Zettinig G, Fueger BJ, Passler C, et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma-surgery or conventional therapy?[J]. Clin Endocrinol, 2002, 56(3): 377-382. DOI: 10.1046/j.1365-2265.2002.01482.x [5] Hindie E, Zanotti-Fregonara P, Keller I, et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome[J]. Endocr Relat Cancer, 2007, 14(3): 799-807. DOI: 10.1677/ERC-07-0120 [6] Mazziotti G, Formenti AM, Panarotto MB, et al. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience[J]. Endocrine, 2018, 59(1): 90-101. DOI: 10.1007/s12020-017-1455-6 [7] Petrich T, Widjaja A, Musholt TJ, et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age[J]. Eur J Nucl Med, 2001, 28(2): 203-208. DOI: 10.1007/s002590000420 [8] Qiu ZL, Song HJ, Xu YH, et al. Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2011, 96(10): 3078-3086. DOI: 10.1210/jc.2011-0093 [9] Wu D, Gomes Lima CJ, Moreau SL, et al. Improved survival after multimodal approach with 131I treatment in patients with bone metastases secondary to differentiated thyroid cancer[J]. Thyroid, 2019, 29(7): 971-978. DOI: 10.1089/thy.2018.0582 [10] Farooki A, Leung V, Tala H, et al. Skeletal-related events due to bone metastases from differentiated thyroid cancer[J]. J Clin Endocrinol Metab, 2012, 97(7): 2433-2439. DOI: 10.1210/jc.2012-1169 [11] 陈春晖, 贾茹, 陈飚. 131I甲状腺癌治疗住院管理及放射防护状况调查[J]. 中国辐射卫生,2022,31(1):64-69. DOI: 10.13491/j.issn.1004-714X.2022.01.012 Chen CH, Jia R, Chen B. An investigation of hospitalization management and radiation protection in 131I treatment for thyroid cancer[J]. Chin J Radiol Health, 2022, 31(1): 64-69. DOI: 10.13491/j.issn.1004-714X.2022.01.012 [12] Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas[J]. J Clin Endocrinol Metab, 2001, 86(4): 1568-1573. DOI: 10.1210/jcem.86.4.7390 [13] Proye CAG, Dromer DHR, Carnaille BM, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine?[J]. World J Surg, 1992, 16(4): 640-645. DOI: 10.1007/BF02067343 [14] Mishra A, Kumar C, Chand G, et al. Long-term outcome of follicular thyroid carcinoma in patients undergoing surgical intervention for skeletal metastases[J]. World J Surg, 2016, 40(3): 562-569. DOI: 10.1007/s00268-016-3402-8 [15] Cazzato RL, Bonichon F, Buy X, et al. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer[J]. Eur J Surg Oncol, 2015, 41(9): 1247-1255. DOI: 10.1016/j.ejso.2015.06.005 [16] Eustatia-Rutten CFA, Romijn JA, Guijt MJ, et al. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma[J]. J Clin Endocrinol Metab, 2003, 88(7): 3184-3189. DOI: 10.1210/jc.2003-030231 [17] Andrade F, Probstner D, Decnop M, et al. The impact of zoledronic acid and radioactive iodine therapy on morbi-mortality of patients with bone metastases of thyroid cancer derived from follicular cells[J]. Eur Thyroid J, 2019, 8(1): 46-55. DOI: 10.1159/000493190 [18] Song HJ, Wu CG, Xue YL, et al. Percutaneous osteoplasty combined with radioiodine therapy as a treatment for bone metastasis developing after differentiated thyroid carcinoma[J]. Clin Nucl Med, 2012, 37(6): e129-e133. DOI: 10.1097/RLU.0b013e31824786d0 [19] Jannin A, Lamartina L, Moutarde C, et al. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival[J]. Eur J Nucl Med Mol Imaging, 2022, 49(7): 2401-2413. DOI: 10.1007/s00259-022-05697-w [20] Choi YM, Kim WG, Kwon H, et al. Early prognostic factors at the time of diagnosis of bone metastasis in patients with bone metastases of differentiated thyroid carcinoma[J]. Eur J Endocrinol, 2016, 175(3): 165-172. DOI: 10.1530/EJE-16-0237 [21] Beasley NJP, Lee J, Eski S, et al. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer[J]. Arch Otolaryngol Head Neck Surg, 2002, 128(7): 825-828. DOI: 10.1001/archotol.128.7.825 [22] Wada N, Masudo K, Nakayama H, et al. Clinical outcomes in older or younger patients with papillary thyroid carcinoma: impact of lymphadenopathy and patient age[J]. Eur J Surg Oncol, 2008, 34(2): 202-207. DOI: 10.1016/j.ejso.2007.10.001 [23] Bardet S, Malville E, Rame JP, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma[J]. Eur J Endocrinol, 2008, 158(4): 551-560. DOI: 10.1530/EJE-07-0603 [24] Wada N, Suganuma N, Nakayama H, et al. Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes[J]. Langenbecks Arch Surg, 2007, 392(4): 417-422. DOI: 10.1007/s00423-007-0159-4 [25] Gillanders SL, O'Neill JP. Prognostic markers in well differentiated papillary and follicular thyroid cancer (WDTC)[J]. Eur J Surg Oncol, 2018, 44(3): 286-296. DOI: 10.1016/j.ejso.2017.07.013 [26] 许艳红, 宋红俊, 邱忠领, 等. 以骨转移为首发症状的分化型甲状腺癌的临床特征与生存分析[J]. 肿瘤,2011,31(6):538-541. DOI: 10.3781/j.issn.1000-7431.2011.06.012 Xu YH, Song HJ, Qiu ZL, et al. Differentiated thyroid carcinoma patients with bone metastasis as the initial presentation: clinical characteristics and survival analysis[J]. Tumor, 2011, 31(6): 538-541. DOI: 10.3781/j.issn.1000-7431.2011.06.012 [27] Orita Y, Sugitani I, Matsuura M, et al. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma[J]. Surgery, 2010, 147(3): 424-431. DOI: 10.1016/j.surg.2009.10.009
